Back to News & Events

Pragma Bio Inks Co-Development Deal with Syntekabio

Pragma Bio, a venture highlighted at the Center for Biotechnology’s 2024 Life Sciences Summit this past fall, has signed a $3.1M deal with Syntekabioto to co-develop drug candidates sourced from gut microbiota. Pragma, which mines microbiome-based therapies for cancer and autoimmune diseases, will provide the compounds and Syntekabio will handle the algorithmic optimization.

Read more about the Pragma, Syteka and their partnership here: https://www.koreabiomed.com/news/articleView.html?idxno=27024

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4559
                    [post_author] => 3
                    [post_date] => 2025-01-14 09:29:08
                    [post_date_gmt] => 2025-01-14 14:29:08
                    [post_content] => 

CNY Biotech Accelerator’s (CNYBAC) Medical Device Innovation Challenge (MDIC) is a 6-month virtual program mentoring selected early-to-mid stage start-up companies each year. The MDIC serves as a complementary and collaborative initiative to assist teams in preparation for incubation programs, expand their innovation ecosystem, and assess strategic planning by providing mentorship, resources, funding/pitch opportunities, and connections. Teams must be US-based and commercializing a medical device per FDA definition.

The initial MDIC Application is accepted January through March 15 each year. Those that fully complete the initial application are sent an Innovation Law Center Supplemental Application to be completed by March 31. Only those applicants that fill out both forms will move on to the selection process.

CNYBAC Medical Device Innovation Challenge (MDIC) Two-step Application Process:
Step 1: Confirm eligibility
Step 2: Complete Innovation Law Center (ILC) Application Review Form

If you meet the eligibility, complete an MDIC Application and return by March 15 to durdonk@upstate.edu.

Reach full eligibility and access application to apply here:
https://cnybac.com/medical-device-innovation-challenge-in-the-national-grid-creation-garage/

[post_title] => Medical Device Innovation Challenge [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => medical-device-innovation-challenge [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:37:25 [post_modified_gmt] => 2025-05-01 16:37:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4559 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2180 [post_author] => 3 [post_date] => 2016-05-03 18:24:23 [post_date_gmt] => 2016-05-03 18:24:23 [post_content] => The Center for Biotechnology has announced the recipients of the 2016-2017 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community and the later-stage commercial development interests of the bioscience industry. The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy. The projects funded include:
  • ICU Temporary Pacemaker - Dr. Wei Lin and Avery Biomedical Device, Inc.
  • Novel Synergistic and Pleiotropic Skin Brightening Agents - Dr. Sanford Simon and Biocogent, LLC
  • Continued In vivo Testing of Vaccine Candidates - Dr. Eckard Wimmer and Cogadenix, Inc.
  • Advanced Fistula-in-Ano Treatment Device - Dr. Tom Zimmerman and Pepper5, Inc.
  • Development of Nanoemulsion-PUFA-taxoids as Tumor-Targeted Chemotherapeutics - Dr. Iwao Ojima and TargaGenix, Inc.
  • Initial Pre-Clinical Safety Assessment of TRB-N0224 - Dr. Lorne Golub and Traverse Biosciences, Inc.
  • Evaluation of a Continuous Visible Light Disinfection System's Ability to Reduce Bioburden and Subsequently the Incidence of Infections and Colonizations in an Active Patient Area - Dr. Annie Rohan and Vital Vio, Inc.
More information about the Applied Research & Development (ARAD) program, as well as all Center for Biotechnology Technology Development programs can be found here. [post_title] => Applied Research and Development Awards Announced [post_excerpt] => The Center for Biotechnology has announced the recipients of the 2016-2017 Applied Research & Development (ARAD) awards. Matching funds have been awarded to seven projects in support of collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => applied-research-and-development-awards-announced [to_ping] => [pinged] => [post_modified] => 2016-05-06 18:19:05 [post_modified_gmt] => 2016-05-06 18:19:05 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2180 [menu_order] => 183 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2364 [post_author] => 4 [post_date] => 2016-08-11 17:51:20 [post_date_gmt] => 2016-08-11 17:51:20 [post_content] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). The Orphan Drug Designation program provides orphan status, and associated development incentives, to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Read more about the designation and company here. iCell [post_title] => iCell Gene Therapeutics Granted Orphan Drug Designation [post_excerpt] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => icell-gene-therapeutics-granted-orphan-drug-designation [to_ping] => [pinged] => [post_modified] => 2017-01-09 15:08:30 [post_modified_gmt] => 2017-01-09 15:08:30 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2364 [menu_order] => 168 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 3 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4559 [post_author] => 3 [post_date] => 2025-01-14 09:29:08 [post_date_gmt] => 2025-01-14 14:29:08 [post_content] =>

CNY Biotech Accelerator’s (CNYBAC) Medical Device Innovation Challenge (MDIC) is a 6-month virtual program mentoring selected early-to-mid stage start-up companies each year. The MDIC serves as a complementary and collaborative initiative to assist teams in preparation for incubation programs, expand their innovation ecosystem, and assess strategic planning by providing mentorship, resources, funding/pitch opportunities, and connections. Teams must be US-based and commercializing a medical device per FDA definition.

The initial MDIC Application is accepted January through March 15 each year. Those that fully complete the initial application are sent an Innovation Law Center Supplemental Application to be completed by March 31. Only those applicants that fill out both forms will move on to the selection process.

CNYBAC Medical Device Innovation Challenge (MDIC) Two-step Application Process:
Step 1: Confirm eligibility
Step 2: Complete Innovation Law Center (ILC) Application Review Form

If you meet the eligibility, complete an MDIC Application and return by March 15 to durdonk@upstate.edu.

Reach full eligibility and access application to apply here:
https://cnybac.com/medical-device-innovation-challenge-in-the-national-grid-creation-garage/

[post_title] => Medical Device Innovation Challenge [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => medical-device-innovation-challenge [to_ping] => [pinged] => [post_modified] => 2025-05-01 12:37:25 [post_modified_gmt] => 2025-05-01 16:37:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4559 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 282 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Medical Device Innovation Challenge

More Information

Applied Research and Development Awards Announced

More Information

iCell Gene Therapeutics Granted Orphan Drug Designation

More Information